The dynamic interaction between matrix metalloproteinase activity and adverse myocardial remodeling

被引:116
作者
Janicki, JS [1 ]
Brower, GL [1 ]
Gardner, JD [1 ]
Chancey, AL [1 ]
Stewart, JA [1 ]
机构
[1] Auburn Univ, Off Res & Grad Studies, Dept Anat Physiol & Pharmacol, Auburn, AL 36849 USA
关键词
ventricular sizer compliance; ventricular function; hypertrophy; cytokines;
D O I
10.1023/B:HREV.0000011392.03037.7e
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The process of cardiac remodeling in response to cardiac injury and/or persistent elevations in wall stress generally relates to the progressive changes that occur in ventricular chamber dimensions and the various components of the myocardium, in particular the cardiomyocytes and the extracellular matrix. Volume overload, pressure overload or myocardial injury produces a sustained abnormal elevation in myocardial wall stress which initiates cardiac remodeling that frequently results in ventricular decompensation and heart failure. Regardless of the inciting cause, there appear to be three distinct phases to this process. In the initial phase, fibrillar collagen is partially degraded secondary to increased matrix metalloproteinase (MMP) activity. Following this, there is a chronic compensatory phase during which MMP activity and collagen concentration return to normal while cardiomyocyte size continues to progressively increase. The final phase is attained once the compensatory hypertrophic mechanisms are exhausted and is characterized by elevated MMP activity, marked ventricular dilatation and prominent fibrosis. Details of this progressive, dynamic remodeling process and its effect on ventricular function during chronic volume overload, chronic pressure overload and following myocardial infarction will be the focus of this article.
引用
收藏
页码:33 / 42
页数:10
相关论文
共 63 条
[31]   Neutralization of interleukin-1β in the acute phase of myocardial infarction promotes the progression of left ventricular remodeling [J].
Hwang, MW ;
Matsumori, A ;
Furukawa, Y ;
Ono, K ;
Okada, M ;
Iwasaki, A ;
Hara, M ;
Miyamoto, T ;
Touma, M ;
Sasayama, S .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 38 (05) :1546-1553
[32]   Tumor necrosis factor-α at acute myocardial infarction in rats and effects on cardiac fibroblasts [J].
Jacobs, M ;
Staufenberger, S ;
Gergs, U ;
Meuter, K ;
Brandstätter, L ;
Hafner, M ;
Ertl, G ;
Schorb, W .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1999, 31 (11) :1949-1959
[33]  
Janicki JS, 2003, PROG EXP CARDIOL, V5, P485
[34]  
JANICKI JS, 1995, BASIC APPL MYOL, V5, P339
[35]   Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas [J].
Kossakowska, AE ;
Edwards, DR ;
Prusinkiewicz, C ;
Zhang, MC ;
Guo, DL ;
Urbanski, SJ ;
Grogan, T ;
Marquez, LA ;
Janowska-Wieczorek, A .
BLOOD, 1999, 94 (06) :2080-2089
[36]   Titin: The "missing link" of diastole [J].
LeWinter, MM .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2000, 32 (12) :2111-2114
[37]   Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor α can be modulated by anti-tumor necrosis factor α therapy [J].
Li, YY ;
Feng, YQ ;
Kadokami, T ;
McTiernan, CF ;
Draviam, R ;
Watkins, SC ;
Feldman, AM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (23) :12746-12751
[38]   MMP inhibition modulates TNF-α transgenic mouse phenotype early in the development of heart failure [J].
Li, YY ;
Kadokami, T ;
Wang, P ;
McTiernan, CF ;
Feldman, AM .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2002, 282 (03) :H983-H989
[39]  
Linzbach A J, 1976, Adv Cardiol, V18, P1
[40]   REGIONAL CHANGES IN HEMODYNAMICS AND CARDIAC MYOCYTE SIZE IN RATS WITH AORTOCAVAL FISTULAS .2. LONG-TERM EFFECTS [J].
LIU, Z ;
HILBELINK, DR ;
GERDES, AM .
CIRCULATION RESEARCH, 1991, 69 (01) :59-65